Teva expects boost from Obamacare; Ohio mulls bill requiring doc-payment disclosure;

@FiercePharma: Sales reps win as Supremes refuse overtime appeals. News | Follow @FiercePharma

> Teva Pharmaceutical Industries says it stands to benefit from the Obama administration's healthcare reform and other plans aimed at getting cheaper medicines to the U.S. market. Article

> Top retail pharmacies are starting to convert Tamiflu capsules into liquid form as demand for that version of the antiviral medication has outpaced supply. News

> Ohio may become the next state to require drugmakers to report gifts they give to doctors. Story

> Teva Pharmaceutical Industries said a September trial date has been set for its ongoing patent infringement litigation against Momenta Pharmaceuticals, Sandoz, Mylan and Natco Pharma regarding their generic versions of multiple sclerosis treatment Copaxone. Item

> Spinal fluid proteins separate Lyme disease from CFS. News 

> Japan's Osaka District Court ordered AstraZeneca to pay 60.5 million yen--about $733,000--to nine of 11 plaintiffs for failing to include proper warnings about serious side effects on its Iressa lung cancer med when it was approved there in July 2002. Report

> Allergan received two subpoenas from the Securities and Exchange Commission over the company's affiliation with Acadia Pharmaceuticals and the sale of Acadia securities, along with other recent inquiries. News

> Biomarkers found for high birth-weight babies. Report 

> Generic drugmaker Mylan added two members to its board, including its president, expanding the panel to 11 directors. Item

> French drugmaker Ipsen posted a 39 percent drop in 2010 net profit and forecast a mixed sales performance for this year as government spending cuts weigh. Report

> Belgian drugmaker UCB warned generic competition to its top epilepsy medicine would cause sales and profits to decline this year, after 2010 beat expectations due to strong sales of the drug. Story

> ADAM12 biomarker could arrest ectopic pregnancy. Item 

Biotech News

@FierceBiotech: Pfizer updates late-stage pipeline prospects and discards. Story  | Follow @FierceBiotech

@JohnCFierce:  Pfizer has been stirring some heated criticism in the UK. Sandwich decision was politically awkward for the PM. Story | Follow @JohnCFierce 

> Another setback for Merck KGaA as FDA spurns cladribine app. Report 

> Ipsen bows out of troubled toremifene pact with GTx. Story 

> India's biotech leaders criticize lack of R&D support. News 

> Lilly outsourcing bioanalytics as part of broad restructuring effort. Article

> Fresh signs of a biotech buyout blast in 2011. News

Drug Delivery News

> ImmunoGen touts new drug-delivering antibodies. Story 

> Zambon unit licenses drug-delivery microdevice from UCSF. Report 

> Valeritas gets FDA nod for V-Go's use with NovoLog. News 

> A closer look at Delcath Systems' refuse-to-file letter. Article 

> Gene-loaded vector destroys breast cancer cells. Item

> Nanoparticles deliver nitric oxide after bleeding trauma. Story

Medical Devices

> Thermo Fisher to build new Chinese facility. Item

> KCI sues to end royalty payments. Report

> Report: Women underrepresented in heart device studies. Article

> Insulet, GSK ink distribution deal. News 

> CardioFocus raises $30.6M. Story

And Finally... High blood pressure medications lower risks in heart patients, even those without hypertension. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.